Trial · NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
NCT02763254, Phase 2, Terminated, Cell Medica Ltd; results first posted 2019-03-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas. Trials, record NCT02763254. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02763254
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
- NCT number
- NCT02763254
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Cell Medica Ltd
- Conditions
- Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder
- Interventions
- baltaleucel-T
- First posted
- 2016-05-05
- Last updated
- 2019-03-26
- Results first posted
- 2019-03-12
- Limitations and caveats
- Early termination leading to small numbers of subjects analyzed.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Overall Response | 1 year | Best single observed response, complete response (CR) or partial response (PR) per Lugano 2014 Disease Response Criteria, during 12 month follow-up. |
| Secondary | Adverse Events | 1 year | Adverse events will be recorded from the time of the first investigational cell product dose is administered until 30 days after the last administration. Serious events recorded for up to 1 year after administration. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Overall Response | 1 year | Subject was withdrawn early before first disease assessment timepoint. | ||
| SECONDARY | Adverse Events | 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adverse Events | Balteleucel-T | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Baltaleucel-T | 1 | |
| Overall Study | COMPLETED | Baltaleucel-T | 0 | |
| Overall Study | NOT COMPLETED | Baltaleucel-T | 1 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Baltaleucel-T | 1 | 1 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Baltaleucel-T | 1 | 1 | 2 |
| other | Platelet Count Decreased | Investigations | Baltaleucel-T | 1 | 1 | 1 |
| serious | Cytokine Release Syndrome | Immune system disorders | Baltaleucel-T | 1 | 1 | 1 |
| serious | Hemophagocytic Lymphohistiosytosis | Blood and lymphatic system disorders | Baltaleucel-T | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Baltaleucel-T | 1 | 1 |
| Total, other adverse events | Baltaleucel-T | 1 | 1 |
| Total, serious adverse events | Baltaleucel-T | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02763254
GET https://conductscience.org/api/trials/v1/NCT02763254/registered